OrbiMed’s NuVasive, Inc. NUVA Stock Holding History

OrbiMed’s Portfolio NUVA Stock Details NUVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-220,700	Closed	-$12.9M	–	150
2017 Q4	$12.9M	Hold	220,700	–	–	0.16%	96
2017 Q3	$12.2M	Buy	220,700 +155,100	+236%	+$10.3M	0.12%	101
2017 Q2	$5.05M	Sell	65,600 -57,900	-47%	-$4.33M	0.05%	114
2017 Q1	$9.22M	Hold	123,500	–	–	0.1%	100
2016 Q4	$8.32M	Hold	123,500	–	–	0.11%	97
2016 Q3	$8.23M	Sell	123,500 -123,600	-50%	-$7.87M	0.09%	109
2016 Q2	$14.8M	Sell	247,100 -1,239,900	-83%	-$67M	0.15%	83
2016 Q1	$72.3M	Hold	1,487,000	–	–	0.76%	41
2015 Q4	$80.5M	Hold	1,487,000	–	–	0.73%	42
2015 Q3	$71.7M	Hold	1,487,000	–	–	0.72%	41
2015 Q2	$70.5M	Buy	1,487,000 +415,000	+39%	+$19.4M	0.59%	49
2015 Q1	$49.3M	Hold	1,072,000	–	–	0.42%	57
2014 Q4	$50.6M	Buy	1,072,000 +410,000	+62%	+$17.1M	0.48%	49
2014 Q3	$23.1M	Buy	662,000 +346,000	+109%	+$12.3M	0.24%	67
2014 Q2	$11.2M	Hold	316,000	–	–	0.13%	79
2014 Q1	$12.1M	Buy	+316,000	New	+$11.6M	0.15%	80

Other funds holding NUVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed's NUVA Position: Q1 2018 in Review

OrbiMed sold out of NuVasive, Inc. (NUVA) in Q1 2018, closing a stake of 220,700 shares — an estimated $12.9M sold.

OrbiMed first reported a position in NUVA in Q1 2014 and held it in 16 quarters. The position peaked at $80.5M in Q4 2015. 279 funds tracked by Wall St. Rank hold NUVA as of Q1 2018.

OrbiMed reported no remaining NuVasive, Inc. position as of Q1 2018 after selling out during the quarter.
OrbiMed sold 220,700 NuVasive, Inc. shares in Q1 2018, an estimated $12.9M.
OrbiMed first reported a position in NuVasive, Inc. in Q1 2014 and held it in 16 quarters.
OrbiMed's NuVasive, Inc. position peaked at $80.5M in Q4 2015.
279 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.